التفاصيل البيبلوغرافية
| العنوان: |
PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE |
| Document Number: |
20110166149 |
| تاريخ النشر: |
July 7, 2011 |
| Appl. No: |
12/866665 |
| Application Filed: |
February 06, 2009 |
| مستخلص: |
The invention provides methods and compositions for treating asthma and/or COPD. For example, provided herein are compositions that include a kinase inhibiting agent such as 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof; and a surfactant. |
| Inventors: |
Dellamary, Luis A. (San Marcos, CA, US); Martin, Michael B. (San Marcos, CA, US) |
| Assignees: |
TARGEGEN INC. (San Diego, CA, US) |
| Claim: |
1. A method for targeting delivery of a pharmaceutical kinase inhibitor composition to the respiratory tract of a patient in need thereof, comprising: administering to the patient a therapeutically effective amount of pharmaceutically acceptable composition suitable for direct delivery to the respiratory tract comprising: (a) from about 0.00001 to about 10% w/v of a kinase inhibiting agent selected from: 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof; and (b) from about 0.00001 to about 10% w/v of a surfactant, wherein the administration results in the drug being predominantly delivered to a mucosal surface of the respiratory tract of the patient and results in a minimal plasma concentration of the kinase inhibiting agent in the patient. |
| Claim: |
2. The method of claim 1, wherein the pharmaceutically acceptable composition further comprises an aqueous based solvent. |
| Claim: |
3. The method of claim 1, wherein the plasma concentration of the agent in the patient is less than about 10 ng/mL within about two hours after administration. |
| Claim: |
4. The method of claim 1, wherein the plasma concentration of the agent is less than about 2 ng/mL. |
| Claim: |
5. The method of claim 1, wherein the surfactant is selected from one or more of: tyloxapol, poloxamer 188, poloxamer 407, Tween™ 80, phosphatidylcholine, phosphatides, or phosphatidyl glycerols. |
| Claim: |
6. The method of claim 1, wherein the surfactant is tyloxapol. |
| Claim: |
7. A composition suitable for administrating by inhalation or nasally, comprising: a) an active agent represented formula I: [chemical expression included] wherein: each of Z2 and Z4 is C, each of Z1, Z3, Z5, and Z6 is N; each X is NH2; each Y is independently selected from a group consisting of —ORd, —NRd2, —SRd, and —OPO3H2, wherein Rd is selected from a group consisting of H, lower alkyl, aryl, and —(CH2)2NH(CH2CH3); or each Y is independently selected from a group consisting of alkyl, substituted alkyl, aryl, substituted aryl, and halogen, wherein said substituents are selected from a group consisting of halogen, —ORe, —NR2—SRe, and —P(O)(OH)2, wherein Re is selected from a group consisting of —H, lower alkyl, and aryl; or each Y is independently selected from a group consisting of CH2glycinyl, CH2NHethoxy, CH2NHCH2alkyl, CH2NHCH2t-Bu, CH2NHCH2aryl, and CH2NHCH2substituted aryl; or when n is 2, each Y is taken together to form a fused aromatic ring system; and m and n are each independently 1 to 4, or pharmaceutically acceptable salts thereof; and b) a surfactant. |
| Claim: |
8. The composition of claim 7, comprising: a) about 0.00001% w/v to about 20% w/v of 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof; b) about 0.00001% w/v to about 6% w/v of a surfactant; and c) water sufficient to make 100% w/v. |
| Claim: |
9. The composition of claim 7, wherein the surfactant is selected from one or more of: tyloxapol, poloxamer 188, poloxamer 407, Tween™ 80, phosphatidylcholine, phosphatides, and phosphatidyl glycerols. |
| Claim: |
10. The composition of claim 7, wherein the surfactant is tyloxapol. |
| Claim: |
11. The composition of claim 7, wherein the composition is in the form of a nebulized aerosol or a powder. |
| Claim: |
12. The composition of claim 8, wherein the composition, when administered to a patient as a nebulized aerosol or dry powder, results in a lung tissue concentration in the patient of at least about 10 ng/g of 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof about 15 minutes after administration. |
| Claim: |
13. The composition of claim 8, wherein the composition, when administered to a patient as a nebulized aerosol or dry powder, results in a plasma concentration in the patient of less than about 5 ng/mL about 15 minutes after administration. |
| Claim: |
14. A method of treating asthma or COPD of a patient in need thereof comprising: administering by inhalation to the patient a composition comprising a therapeutically effective amount of the active agent 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof and a surfactant, thereby delivering to the mucus membranes of the lungs of the patient a pharmaceutically effective amount of the active agent. |
| Claim: |
15. The method of claim 14 wherein the method of treating COPD is a method of treating emphysema. |
| Claim: |
16. The method of claim 14, wherein the method of treating COPD is a method of treating chronic bronchitis. |
| Claim: |
17. The method of claim 14, wherein the surfactant is selected from one or more of: tyloxapol, poloxamer 188, poloxamer 407, Tween™ 80, phosphatidylcholine, phosphatides, and phophatidyl glycerols. |
| Claim: |
18. The method of claim 14, wherein the surfactant is tyloxapol. |
| Claim: |
19. A kit for treating a respiratory disease, the kit comprising (a) a composition comprising 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof, and a non-ionic surfactant, in a sealed container, and (b) a label indicating administration by inhalation or nasally. |
| Claim: |
20. The kit of claim 19, wherein the composition comprises 0.05 mg to 40 mg of 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof. |
| Current U.S. Class: |
514/249 |
| Current International Class: |
61; 61; 61; 61 |
| رقم الانضمام: |
edspap.20110166149 |
| قاعدة البيانات: |
USPTO Patent Applications |